Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL759761 | 1.00 | CYP1A2 (0.57) | CYP1A2KMT2APOLBL3MBTL1NOD1 | |
| SCHEMBL3950974 | 0.94 | CYP1A2 (0.55) | CYP1A2KMT2APOLBL3MBTL1NOD1 | |
| SCHEMBL11456748 | 0.93 | CYP1A2 (0.53) | CYP1A2KMT2APOLBL3MBTL1NOD1 | |
| SCHEMBL11081103 | 0.93 | CYP1A2 (0.53) | CYP1A2KMT2APOLBL3MBTL1NOD1 | |
| SCHEMBL374738 | 0.88 | L3MBTL1 (0.53) | CYP1A2KMT2APOLBL3MBTL1NOD1 | |
| SCHEMBL207116 | 0.88 | L3MBTL1 (0.53) | CYP1A2KMT2APOLBL3MBTL1NOD1 | |
| SCHEMBL573710 | 0.88 | L3MBTL1 (0.53) | CYP1A2KMT2APOLBL3MBTL1NOD1 | |
| Hydrochloric Acid SCHEMBL2012219 | 0.86 | L3MBTL1 (0.51) | CYP1A2KMT2APOLBL3MBTL1NOD1 | |
| Hydrochloric Acid SCHEMBL134419 | 0.86 | L3MBTL1 (0.51) | CYP1A2KMT2APOLBL3MBTL1NOD1 | |
| SCHEMBL20270768 | 0.86 | L3MBTL1 (0.51) | CYP1A2KMT2APOLBL3MBTL1NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |
| EP-1765785-B1 | PROSTAGLANDIN ANALOGS | ALLERGAN INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7326698-B2 | Prostaglandin analogs | ALLERGAN, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1765785-A1 | PROSTAGLANDIN ANALOGS | Allergan, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20070054893-A1 | Prostaglandin analogs | ALLERGAN, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20060154922-A1 | Muscarinic agonists | ELILILLY AND COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006014206-A1 | PROSTAGLANDIN ANALOGS | ALLERGAN, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| EP-1608619-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004094382-A1 | MUSCARINIC AGONISTS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-0137640-A1 | Chain extended analogues of methotrexate and aminopterin | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1985-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154922-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | CYP1A2 500/4885KMT2A 2193/4885POLB 3647/4885 |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | CYP1A2 3367/4885KMT2A 244/4885POLB 624/4885 |
| US-20070054893-A1 | Prostaglandin analogs | PTGIS, PTGES, PTGIR | CYP1A2 396/4885KMT2A 4582/4885POLB 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.